Be a native speaker of English or Spanish
Not fluent in other languages
No history of neurological or language disorders
Normal or normal-to-corrected vision
Right-handed
Native speaker of a language different from English or Spanish
Older than 45 years old
Left-handed or ambidextrous
A history of neurological disorders or language disorders

18 years of age and older
English speaking individuals
under 18 years old
non english-speaking individuals

Patient with histologically confirmed unilateral primary invasive adenocarcinoma of the breast with a date of initial cytologic or histologic diagnosis within 18 months prior to randomization
Patient has breast cancer that is positive for ER and/or PgR
Patient has HER2-negative breast cancer defined as a negative
Patient has available archival tumor tissue from the surgical specimen, for submission to a central laboratory.
If indicated, patient has completed adjuvant and/or neoadjuvant chemotherapy according to the institutional guidelines
Patient has received any CDK4/6 inhibitor
Patient has received prior treatment with tamoxifen, raloxifene or AIs
Patient has received prior treatment with anthracyclines at cumulative doses of 450 mg/m² or more for doxorubicin, or 900 mg/m² or more for epirubicin.
h a known hypersensitivity to any of the excipients of ribociclib and/or ET (
Patient with distant metastases of breast cancer beyond regional lymph nodes

Diagnosis of CLL according to the NCI/IWCLL criteria or SLL according to the WHO criteria
Negative FISH analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy
Age ≥ 18 years and < 70.
ECOG performance status between 0-2.
Life expectancy of ≥ 12 months.
No deletion of 17p13 on cytogenetic analysis by FISH
No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment.
No current use of corticosteroids.
No previous autoimmune complications
No other active primary malignancy

User of the Story feature on Snapchat or Instagram
At least 18 years old
Anyone under the age of 18 years old
Non users of social media

Histologic documentation of women or men with HER2 negative breast carcinoma and free of recurrence.
Prior adjuvant treatment with chemotherapy and/or endocrine therapy, as determined by the treating physician, is allowed.
Age > 18 and < 70 years of age.
ECOG performance status 0-2.
Patients with a prior history of gastric/duodenal ulcers documented on endoscopy can be enrolled as long as the ulcers did not cause bleeding requiring a blood transfusion/major intervention.
No history of GI bleeding requiring a blood transfusion, endoscopic or operative intervention.
No history of any prior stroke (hemorrhagic or ischemic).
No concurrent anticoagulation with warfarin, heparin/heparin analogues, clopidogrel, direct thrombin inhibitors, or direct factor XA inhibitors.
No history of atrial fibrillation or myocardial infarction.
No history of grade 4 hypertension, defined as hypertension resulting in lifethreatening consequences

forestry or climate science related majors (include but not limited to agricultural sciences, environmental resources management, forest ecosystem management, plant science, ecology, biology, meteorology and atmospheric science)
undergraduate or graduate students at Penn State University who are older than 18.
participants should be healthy (without contagious disease)
people under 18
people who are cognitively impaired
people who have contagious disease

Individuals who had some experience with chronic pain over the last 6 months
Living in homes with internet access
Willing to use a smart-home device (Amazon Alexa)
Have access to a smart phone
Read, write, and speak English
Under 18 years old
Major mental health issue that is not currently under advisement of a doctor/therapist
Actively struggling with addiction to substances or newly in recovery
Participants who currently report using mindfulness practices more than 1x a month

18 years and older
Working towards a degree in a field requiring high vocal demand (e.g. future teachers, lawyers, voice performers including singers and actors)
Currently being treated for a voice disorder

Ages 21-70
Smoke 5 or more cigarettes per day
Must be willing to both switch to a different type of cigarette and try an electronic cigarette
No serious quit attempt or use of smoking cessation medication in the past 30 days
Meet diagnostic criteria for current or lifetime mental health condition
Women who are pregnant, nursing, or trying to become pregnant
Any known allergy to propylene glycol or vegetable glycerin
History of difficulty providing blood samples
Other member of the household currently participating in the study
Unstable or significant medical condition in the past 3 months

At least 18 years of age
Fluent in english
Individual with a physical disability (eg. limb amputation, spinal cord injury, spinabifida, cerebralpalsy, arthritis, motor impairment)
Has participated in physical therapy in the last year
Under the age of 18
Does not speak fluent english
does not have a physical disability
Has not participated in physical activity in the last year

moderate to severe crohn's disease, 3 months
failed prior treatment
severe or fulminant colitis requiring surgery
presence of stoma, gastric pouch
prior bowel resection, 6 months
bleeding disorders
cancer < 5 years

65 or older
no diagnosis of dementia
available for 6 months
64 or younger
dementia or motor movement disorder diagnosis
cognitive training within past 2 years

PN involving 2 affected areas
Willing to follow all study directions and attend appointments
PN affecting only 1 part of the body
Certain diagnosis associated with PN are not allowed, coordinator will discuss specifics

Taken at least 10 Uber/Lyft ride in the last 12 months.
You are willing to share several of your past Uber/Lyft trip records in the app with us.
You are a current or past employee with one of the ride-sharing corporations (Uber/Lyft)

age 18-80
Have high blood pressure despite taking blood pressure medicine
You have not donated a kidney
You have had removal of a kidney or kidney transplant
You have type 1 diabetes or severe type 2
Have severe untreated obstructive sleep apnea
Bleeding disorder

Men and women of all races
18- 60 years old
Previously Diagnosed with POTS or healthy people without chronic illness
Capable of giving informed consent
Age <18 years or >60 years
Pregnant or breastfeeding women
Other potential causes for tachycardia (e.g. prolonged bed rest, dehydration)
Taking stimulant medications within the past 3 months as these may alter cognition
Unable to tolerate an MRI scanner (e.g. claustrophobia, implanted metal)

Over 18 in age
English is first language
Right-handed
No history of neurological injury or disease
Under 300 lbs in weight
Claustrophobic
Taking medication that affects brain or blood flow

Individuals must be 18 years of age or older
Individuals must be an undergraduate OR graduate student at Penn State
Individuals under the age of 18
Individuals who are not an undergraduate OR graduate student at Penn State

Age 60 and older
Female
Breast Cancer Survivor
Preparing to Start AI medication
ER+ diagnosis
Already taking AI medication (greater than 24 weeks)
Gross Cognitive Impairment
Recent Joint Surgery
Cardiac event/Stroke within last 6 months
Not willing to come to HMC for Exercise Sessions

Diagnosed with a neuromuscular condition
Unwilling to provide informed consent

Currently enrolled as a master’s or doctoral student in a counseling education program
18 years of age or older
Capable of providing informed consent without the assistance of a legal guardian
Identify as a racial or ethnic minority
Able to understand written and spoken English at the time of the survey
Adults unable to consent
Individuals who are not yet adults (infants, children, teenagers)

Cannabis Use
Between 18-30 years old
Recreationally trained
Able to read write English and complete study evaluations
Provide negative toxicology screenings for nicotine or alcohol at intake
Women who are pregnant or lactating
Known endocrine disorder
Blood clotting disorders
Any psychiatric disorder or current psychiatric symptoms
Inability to give informed consent

Participants must be between the ages of 18 and 45.
Participants must be right handed.
Participants must be fluent English speakers.
Participants must have a body mass index (BMI) >= 25.
Participants must have experienced food eating/weight issues.
If participants are currently engaging in active dieting behaviors (e.g., a weight loss program) or they are taking medications that could alter appetite or body weight.
If participant have a lifetime history of diagnosed eating disorders, diabetes, hyperglycemia, high levels of triglycerides, or high cholesterol or other related medical conditions.
If participants have any known risk from exposure to high-field strength magnetic fields (e.g., pace makers), any irremovable metallic foreign objects in their body (e.g., braces), or a questionable history of metallic fragments.
If participants report that they are vegetarian/vegan.
If participants are not willing to refrain from using alcohol for 24 hours or from using nicotine products/recreational drugs for 3 weeks, or unwilling to fast from food for 5 hours prior to two of three lab visits.

1. Diagnosis of aphasia
2. Sustained stroke more than 6 months prior to consent
3. Native speakers of English
4. Completed at least a high school education
5. Normal or corrected-to-normal vision and hearing
1. History of degenerative neurological disorders (e.g., Alzheimer’s disease), acquired neurological disorders other than aphasia from stroke (e.g., traumatic brain injury), developmental neurological disorders (e.g., autism), or psychiatric disorders
2. An active medical condition that could compromise participation (e.g., cancer undergoing acute treatment)
3. Taking medications that are known to exert significant effects on cognitive processes
4. Do not meet the above inclusionary criteria

Must have histologically confirmed (biopsy-proven) diagnosis of mantle cell lymphoma (MCL)
Must have measurable or evaluable disease as defined as a lymph node measuring >1.5 cm in any dimension or splenomegaly with spleen >15 cm in craniocaudal dimension
ECOG performance status of 0-2
Adequate organ function as measured by the criteria
Total Bilirubin ≤ 1.5x upper limit of normal (ULN) or ≤ 3x ULN with documented Gilbert’s syndrome
Should not have known evidence of central nervous system (CNS) lymphoma
Should not have prior chemotherapy, radiotherapy or immunotherapy for lymphoma
Must not have received a prior allogeneic stem cell transplant or solid organ transplant (except for cornea) for any indication
Must have no active, uncontrolled infections
Must not have active hepatitis B or be chronic carriers of hepatitis B.

healthy females and males
all minorities and ethnicies included
free of acute or chronic medical conditions
over 21 years old
Females who are pregnant or lactating
under 21 years old
Decisional impairment

Patients must have had a confirmed diagnosis of symptomatic multiple myeloma (See Section 4.1) that required systemic induction therapy prior to autologous stem cell transplantation (ASCT).
Patients with disease measurable by serum light chain assay alone are eligible (defined as ≥ 100 mg/L on involved light chain).
Patients must be ≥ 18 and ≤ 75 years of age at time of registration to Step 1.
Patients must have history and physical exam within 28 days prior to registration.
Patients must have Zubrod Performance Status ≤ 2.
Patients with smoldering myeloma are not eligible
Patients must not have any organ involvement by amyloidosis or evidence of amyloidosis related organ dysfunction.
Patients must not have progressive disease at any time prior to registration.
Patients must not be refractory or intolerant to either lenalidomide or daratumumab/rHuPH20.
Patients must not have moderate or severe persistent asthma within the past 2 years and must not have currently uncontrolled asthma of any classification.

Over 18 years of age
Ability to communicate in written and spoken English
Able to give informed consent
Below 18 years of age
Unable to communicate in written and spoken English
Unable to give informed consent

Surgically resected non-small cell lung cancer
Pathologic stage IIIA, II (IIA or IIB) or large IB (defined as size ≥4 cm).
Tissue available for the required analyses
No patients with recurrence of lung cancer after prior resection
No prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD1/PD-L1/CTLA-4.